Magnetic Blood Filtration” (MBF) is a first-of-its-kind drug/device combination platform that enables the removal of specific substances from the bloodstream. MBF can be used either as a direct treatment, to increase the safety and efficacy of other therapies, or enable personalised medicine. We have the ambition to become a global player, providing hospitals with a new tool to tackle some of mankind’s most serious diseases.

Keep In Touch

A spin-out from University College London, MediSieve is a multi-award-winning company dedicated to the development and commercialisation of MBF. The company has raised a total of £4M in equity funding and won grants worth a total of over £4M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. We closed a £1.8M Series A in May 2021, and in December 2020 secured a £1.6M grant from the UKRI to support clinical trials, which are due to start in 2021.

Our multidisciplinary team has experience across various fields of science and technology development.


Neil Barker Joins MediSieve as a Quality Manager

Neil Barker Joins MediSieve as a Quality Manager
September 06, 2021

MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today announced the appointment of Neil Barker, as a Quality Manager. Neil brings to MediSieve a 40-year track record in quality and regulatory affairs, having held management positions at multiple engineeri...